Literature DB >> 9224960

A randomized, double-blind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum.

W Bonnez1, D Oakes, A Bailey-Farchione, A Choi, D Hallahan, L Corey, G Barnum, P G Pappas, M Halloway, M H Stoler, R C Reichman.   

Abstract

Forty-nine subjects were enrolled in a study comparing two dosages of parenterally administered interferon (IFN)-beta in combination with cryotherapy for the treatment of anogenital warts. Subjects were randomized to receive subcutaneous injections of either 2 x 10(6) or 4 x 10(6) IU/m2 of IFN-beta (Biogen) three times a week for a total of 6 weeks. Cryotherapy was administered concomitantly by aerosolization of liquid nitrogen at 10-day intervals. Systemic side- effects were modest in intensity and included fever, chills, myalgia, and headaches (flu-like symptoms). During the first 2 weeks of therapy, they were more common in the high dose group than in the low dose group (P = 0.02). Using survival analysis, there was no significant difference between the two groups in rates of resolution of warts present at baseline (P = 0.62). However, the rate of new lesion formation during the study was significantly lower in the high dose group (P = 0.04).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224960     DOI: 10.1016/s0166-3542(97)01037-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  2 in total

Review 1.  Interferon-beta therapy in multiple sclerosis: evidence for a clinically relevant dose response.

Authors:  D S Goodin
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  Interferon-Tau has Antiproliferative effects, Represses the Expression of E6 and E7 Oncogenes, Induces Apoptosis in Cell Lines Transformed with HPV16 and Inhibits Tumor Growth In Vivo.

Authors:  Herbey Oswaldo Padilla-Quirarte; Cesar Trejo-Moreno; Geny Fierros-Zarate; Jhoseline Carnalla Castañeda; Marie Palma-Irizarry; Eva Hernández-Márquez; Ana Isabel Burguete-Garcia; Oscar Peralta-Zaragoza; Vicente Madrid-Marina; Kirvis Torres-Poveda; Victor Hugo Bermúdez-Morales
Journal:  J Cancer       Date:  2016-11-05       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.